高级检索
当前位置: 首页 > 详情页

A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of a Nicotine Mint Lozenge (2 and 4 mg) in Smoking Cessation

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China [2]Tobacco Medicine and Tobacco Cessation Center, China-Japan Friendship Hospital, Beijing, China [3]National Clinical Research Center for Respiratory Diseases, Beijing, China [4]GlaxoSmithKline Consumer Healthcare, Parsippany, NJ [5]Department of Respiratory Medicine, The First Hospital of China Medical University, Shenyang, China [6]Institute of Respiratory Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
出处:
ISSN:

关键词: nicotine lozenge nicotine replacement therapy quit attempts smoking cessation

摘要:
Objective: To evaluate the efficacy in smoking cessation and safety of 2 and 4 mg nicotine mint lozenges in Chinese adult smokers. Methods: This was a multicenter, randomized, stratified, double-blind, placebo-controlled, parallel-group study. The low-dependence stratum included 483 smokers (241 randomized to active 2 mg nicotine lozenge and 242 to placebo lozenge). The high-dependence stratum included 240 smokers (120 randomized to active 4 mg nicotine lozenge and 120 to placebo lozenge). The primary endpoint was successful smoking cessation at 6 weeks postquit, defined as continuous abstinence from smoking for the 28-day period up to and including the 6-week visit (verified by CO measurement). Cochran-Mantel-Haenszel tests were performed to compare quit rates between active nicotine and placebo separately for the high-dependence and low-dependence strata. Results: The primary analysis showed that in the low-dependence (2 mg) stratum, 59 subjects (24.5%) of 241 in the active nicotine group and 52 subjects (21.5%) of 242 in the placebo group were successful quitters (P = .3851). In the high-dependence (4 mg) stratum, 37 subjects (30.8%) of 120 in the active nicotine group and 24 subjects (20.2%) of 119 in the placebo group were successful quitters (P = .0565). Conclusions: The 4 mg nicotine lozenge provided a directionally significant improvement in smoking cessation rates compared with placebo in Chinese adult smokers with high nicotine dependence for the primary endpoint. The 2 mg nicotine lozenge provided higher, but nonsignificant, smoking cessation rates than placebo. Both nicotine lozenges were generally well tolerated in Chinese adult smokers.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 3 区 医学
小类 | 4 区 药物滥用
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 药物滥用
JCR分区:
出版当年[2018]版:
Q3 SUBSTANCE ABUSE
最新[2023]版:
Q1 SUBSTANCE ABUSE

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2018版] 出版当年五年平均[2014-2018] 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者单位: [1]Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China [2]Tobacco Medicine and Tobacco Cessation Center, China-Japan Friendship Hospital, Beijing, China [3]National Clinical Research Center for Respiratory Diseases, Beijing, China
通讯作者:
通讯机构: [1]Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China [3]National Clinical Research Center for Respiratory Diseases, Beijing, China [6]Institute of Respiratory Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China [*1]China-Japan Friendship Hospital, 2 Yinghuayuan E St, Chaoyang Qu, Beijing, 100029, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)